Dutogliptin tartrate is under clinical development by Recardio and currently in Phase II for Post-Myocardial Infarction. According to GlobalData, Phase II drugs for Post-Myocardial Infarction have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dutogliptin tartrate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dutogliptin tartrate overview
Dutogliptin tartrate (REC-01) is under development for the treatment of acute and post myocardial infarction. The therapeutic candidate is formulated as solution and administered through subcutaneous route. The drug candidate is a DPP-IV inhibitor and is also given in combination with G-CSF.
Recardio is a life science company that focuses on drug-based regenerative therapeutic modalities for treatments of cardiovascular diseases. The company is headquartered in San Francisco, California, the US
For a complete picture of Dutogliptin tartrate’s drug-specific PTSR and LoA scores, buy the report here.